Grade: Pharmaceutical Grade

Factory Location: Quanzhou

Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

Sample Provided: no

Payment Terms: L/C

Bortezomib is the first proteasome inhibitor approved by the U.S. FDA for multiple myeloma, a blood cancer. Reversible inhibitor of 26S proteasome, a bark-shaped polyprotein particle, found in the nucleus and cytoplasm of all eukaryotic cells. Targeting the ubiquitin-proteasome pathway.